In the validation set, there was a statistically significant difference in the expression of IL1B and EGR1 between the NAFLD group and the control group (p<0.0001 and 0.001 respectively), but it was weakly correlated with fibrosis staging. Here, IL1B is linked to metabolic dysfunction-associated steatotic liver disease.